EDIT — Editas Medicine Inc

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

About Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$3.43
Market Cap$264M
Float97.6M
Shares Outstanding97.9M
Price/Sales (TTM)6.83
vs. Analyst Target+68.4% to analyst PT
Profit Margin-281.59%
Operating Margin (TTM)-883.19%
Revenue (TTM)$38.7M
Dividend RateNone
Analyst Target Price$5.78 (15 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 $90.7M -$109M $90.7M -$131M
2021 $25.5M -$185M $25.5M -$188M
2022 $19.7M -$204M $19.7M -$220M
2023 $78.1M -$153M $72.1M -$163M
2024 $32.3M -$237M $32.3M -$233M
2025 $40.5M -$160M $40.5M -$149M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Jun 2025 $3.6M -$53.2M
Sep 2025 $7.5M -$25.1M
Dec 2025 $24.7M -$5.6M
Mar 2026 $2.8M -$25.0M

Ownership & Float

Insider Ownership0.3%
Institutional Ownership54.9%
Short Float10.2%
% of All Funds Holding2.34%
Number of Funds Holding192

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$2.91Near-term / short-term trend
Weekly40-Week SMA$2.63Medium-term trend
Weekly80-Week SMA$2.23Cyclical trend (business cycle)
Weekly200-Week SMA$5.85Secular trend (multi-year)
Monthly10-Month SMA$2.67Near-term monthly trend
Monthly20-Month SMA$2.28Medium-term monthly trend
Monthly40-Month SMA$4.81Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$7.40 resistance 1.03x 24 months ago
$10.00 resistance 1.08x 26 months ago

Historical Earnings Reactions (42 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap 0.59% 0.56% 57.14% 6.99% -4.99%
1 Day 2.06% 0.91% 50.00% 34.50% -9.46%
1 Week 1.63% 1.81% 54.76% 41.91% -31.63%
2 Weeks 0.70% -1.75% 42.86% 30.96% -31.73%
1 Month 1.84% 0.40% 51.22% 60.32% -37.94%

Next earnings: July 24, 2026 (55 days away)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

MonthAvg ReturnWin RateSamples
Jan-4.9%40.0%10
Feb7.5%50.0%10
Mar-5.4%36.4%11
Apr-0.3%45.5%11
May0.1%50.0%10
Jun9.0%60.0%10
Jul3.6%70.0%10
Aug3.6%60.0%10
Sep-7.6%20.0%10
Oct-5.9%40.0%10
Nov7.1%50.0%10
Dec2.3%30.0%10

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday 0.18% 49.5% 483
Tuesday 0.14% 51.1% 534
Wednesday 0.49% 50.6% 530
Thursday -0.23% 44.4% 522
Friday -0.22% 46.0% 522

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 54.9%

Insider Transactions — Smart Summary

Total insider ownership: 0.3%

12-Month Insider Activity Summary

Total Filings14
Net Value-$88,230.671
Net Shares Change-42,318
% of Float-0.0%
C-Suite Filings14
Clusters Detected4

Key Insiders

NameTitleNet ValueFilingsActivity
O'Neill Gilmore Neil CEO -$63,671.038 4 N/A
Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER -$15,804.764 3 N/A
Parison Amy SVP, Chief Financial Officer -$3,139.073 3 N/A

Transaction Clusters

PeriodFilingsInsidersNet ValueSeniority
2025-06-04 – 2025-06-04 3 3 -$28,216.311 3 C-suite
2025-09-04 – 2025-09-04 3 3 -$17,549.636 3 C-suite
2025-12-04 – 2025-12-04 3 3 -$14,591.559 3 C-suite
2026-03-04 – 2026-03-04 3 3 -$13,364.422 3 C-suite

Significant Filings

DateInsiderTitleNet ValuePrice After
2025-08-04 Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER -$12,756.923 Transaction at $2.49, now +37.7%
2025-06-04 O'Neill Gilmore Neil CEO -$26,195.566 Transaction at $1.72, now +98.9%
2025-12-04 O'Neill Gilmore Neil CEO -$12,063.819 Transaction at $2.15, now +59.3%
2026-03-04 Parison Amy SVP, Chief Financial Officer -$957.48 Transaction at $2.02, now +69.8%
2026-03-04 O'Neill Gilmore Neil CEO -$10,894.262 Transaction at $2.02, now +69.8%
2026-03-04 Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER -$1,512.68 Transaction at $2.02, now +69.8%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Editas Medicine Inc (EDIT) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for EDIT on Trend Edge →